CHMP Adopts Positive Opinion for BAVENCIO® (avelumab) Plus Axitinib for First-Line Treatment of Patients with Advanced Renal Cell Carcinoma

ROCKLAND, MA and NEW YORK, US, September 20, 2019 /PRNewswire/ — EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European…

Source: https://www.prnewswire.com:443/news-releases/chmp-adopts-positive-opinion-for-bavencio-avelumab-plus-axitinib-for-first-line-treatment-of-patients-with-advanced-renal-cell-carcinoma-300922329.html